Analyzing Kura Oncology (KURA) & The Competition
Kura Oncology (NASDAQ: KURA) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare Kura Oncology to similar businesses based on the strength of its earnings, dividends, analyst recommendations, risk, profitability, valuation and institutional ownership.
This table compares Kura Oncology and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Kura Oncology Competitors||-5,302.25%||-218.50%||-39.57%|
Kura Oncology has a beta of 4.87, suggesting that its share price is 387% more volatile than the S&P 500. Comparatively, Kura Oncology’s peers have a beta of 6.15, suggesting that their average share price is 515% more volatile than the S&P 500.
This is a summary of current recommendations for Kura Oncology and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Kura Oncology Competitors||866||3223||11702||232||2.71|
Kura Oncology currently has a consensus target price of $18.13, indicating a potential upside of 27.19%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.10%. Given Kura Oncology’s peers higher possible upside, analysts clearly believe Kura Oncology has less favorable growth aspects than its peers.
Insider and Institutional Ownership
64.3% of Kura Oncology shares are held by institutional investors. Comparatively, 50.0% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 21.8% of Kura Oncology shares are held by company insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Kura Oncology and its peers revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Kura Oncology||N/A||-$27.56 million||-9.19|
|Kura Oncology Competitors||$284.49 million||$33.78 million||82.67|
Kura Oncology’s peers have higher revenue and earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
About Kura Oncology
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that targets cell-signaling pathways, which drives the progression of certain cancers. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with tumors that have mutations in or other dysregulation of the mitogen-activated protein kinase (MAPK), signaling pathway, including pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma.
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.